Clinical Study on Litozin to be presented at 10th World Congress on Osteoarthritis

Green Bay, WI (November 21, 2005) – A recent study involving LitoZin®, the newest generation of joint health supplements, will be presented at the Osteoarthritis Research Society International World Congress in Boston, Massachusetts on December 8, 2005. The study’s principal author, Dr Kaj Winther, will present a poster detailing the effect of Litozin on decreasing cholesterol levels, as well as alleviating symptoms of osteoarthritis.

The study, published recently in the Scandinavian Journal of Rheumatology, demonstrates that there was a significant reduction, 82%, in joint discomfort after 3 weeks of treatment with LitoZin®. Additionally, the consumption of rescue medicine also declined significantly in the active treatment group. WOMAC pain significantly declined (p<0.02) as compared to placebo, after 3 weeks of treatment. The study’s results support the findings on earlier clinical studies published by the same group as well as studies by other independent groups. The study also demonstrated significant decline in cholesterol levels (p<0.05), which is the subject of Dr Winther’s poster presentation.

This most recent study, A powder made from seeds and shells of a rose-hip subspecies (Rosa canina l.) reduces symptoms of knee and hip osteoarthritis: A randomized, double-blind, placebo-controlled clinical trial, Scand J Rheumatol 34:302-308, 2005 by Winther, K. Apel, K and Thomsborg,G., is the continuation of an extensive series of laboratory and clinical investigations on anti-inflammatory and efficacy of rose hip in osteoarthritis. The Scandinavian Journal of Rheumatology is one of the leading international journals in the field of arthritis and rheumatology.

The proprietary extract, made from a unique Danish wild rose hip, subspecies rosa canina lito, is being imported into the US by Terry Lemerond, a pioneer in discovering and bringing to North America natural dietary supplements with significant research behind them. Lemerond’s company, EuroPharma, has secured the North American rights to LitoZin® and is in talks with partner companies to market Litozin in the US.

Located in Green Bay, Wisconsin, EuroPharma, Inc., is committed to discovering innovative products that have been extensively researched and demonstrated to be safe, natural and effective which will help people live healthier and more fulfilling lives. EuroPharma’s mission is to bring truly unique and industry changing products to the U.S. marketplace. EuroPharma is an extension of its founder, Terry Lemerond’s historic successes and a proven model of product development. For more information, visit


Suzanne Shelton
[email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.